Lung cancer study explores new drug combo after treatment fails
Disease control
Completed
This study tested a drug called cabozantinib, given alone or with another drug called erlotinib, in 92 adults with advanced non-small cell lung cancer. Participants had already tried erlotinib and their cancer had gotten worse. The goal was to find a safe dose and see if the comb…
Phase: PHASE1, PHASE2 • Sponsor: Exelixis • Aim: Disease control
Last updated May 13, 2026 16:02 UTC